See more : Class Editori Spa (CLE.MI) Income Statement Analysis – Financial Results
Complete financial analysis of Aravive, Inc. (ARAV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aravive, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Walmart Inc. (WMT.NE) Income Statement Analysis – Financial Results
- Hui Lyu Ecological Technology Groups Co.,Ltd. (001267.SZ) Income Statement Analysis – Financial Results
- Unisync Corp. (UNI.TO) Income Statement Analysis – Financial Results
- Fortis Inc. (FTS.TO) Income Statement Analysis – Financial Results
- Shanghai Prosolar Resources Development Co., Ltd (600193.SS) Income Statement Analysis – Financial Results
Aravive, Inc. (ARAV)
About Aravive, Inc.
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.14M | 7.44M | 5.69M | 4.75M | 1.37M | 40.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 66.94M | 37.54M | 17.62M | 12.84M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -57.80M | -30.10M | -11.94M | -8.08M | 1.37M | 40.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -632.60% | -404.45% | -209.94% | -170.06% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 66.94M | 37.54M | 17.62M | 12.84M | 11.08M | 94.61M | 71.98M | 60.03M | 32.61M | 14.86M | 10.96M | 6.37M |
| General & Administrative | 13.04M | 10.55M | 13.07M | 13.69M | 27.40M | 29.87M | 24.34M | 22.48M | 13.51M | 4.43M | 1.94M | 1.78M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.04M | 10.55M | 13.07M | 13.69M | 27.40M | 29.87M | 24.34M | 22.48M | 13.51M | 4.43M | 1.94M | 1.78M |
| Other Expenses | -5.49M | 1.46M | -14.00K | 2.53M | 519.00K | -1.59M | 236.00K | 113.00K | -11.53M | 913.00K | 75.00K | 10.00K |
| Operating Expenses | 79.97M | 48.09M | 30.69M | 26.53M | 38.47M | 124.48M | 96.32M | 82.51M | 46.11M | 19.28M | 12.90M | 8.16M |
| Cost & Expenses | 79.97M | 48.09M | 30.69M | 26.53M | 38.47M | 124.48M | 96.32M | 82.51M | 46.11M | 19.28M | 12.90M | 8.16M |
| Interest Income | 653.00K | 37.00K | 255.00K | 1.02M | 989.00K | 847.00K | 514.00K | 218.00K | 132.00K | 1.00K | 0.00 | 0.00 |
| Interest Expense | 4.60M | 0.00 | 0.00 | 0.00 | 2.43M | 0.00 | 0.00 | 0.00 | 0.00 | 128.00K | 393.00K | -130.00K |
| Depreciation & Amortization | 886.00K | 974.00K | 11.57M | 3.56M | 1.06M | 311.00K | 215.00K | 194.00K | 107.00K | 17.00K | 21.00K | 20.00K |
| EBITDA | -70.84M | -40.65M | -19.22M | -18.22M | -35.59M | -84.48M | -96.32M | -82.51M | -57.51M | -18.35M | -12.80M | -7.28M |
| EBITDA Ratio | -775.28% | -546.21% | -338.01% | -383.29% | -2,595.99% | -211.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -70.84M | -40.65M | -30.78M | -21.77M | -75.41M | -84.48M | -96.32M | -82.51M | -46.11M | -19.28M | -12.90M | -8.16M |
| Operating Income Ratio | -775.28% | -546.21% | -541.50% | -458.11% | -5,500.51% | -211.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -5.49M | 1.50M | 241.00K | 3.56M | -921.00K | -744.00K | 750.00K | 331.00K | -11.40M | 786.00K | -318.00K | 990.00K |
| Income Before Tax | -76.32M | -39.15M | -30.54M | -18.22M | -76.33M | -85.23M | -95.57M | -82.18M | -57.51M | -18.50M | -13.22M | -7.17M |
| Income Before Tax Ratio | -835.31% | -526.08% | -537.26% | -383.29% | -5,567.69% | -213.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 4.60M | -1.01M | 3.70M | 2.04M | 1.51M | -247.00K | 247.00K | -412.00K | -11.64M | 1.04M | 468.00K | 860.00K |
| Net Income | -80.92M | -38.14M | -34.24M | -20.25M | -76.33M | -84.98M | -95.82M | -82.18M | -57.51M | -18.50M | -13.22M | -7.17M |
| Net Income Ratio | -885.64% | -512.50% | -602.34% | -426.13% | -5,567.69% | -212.45% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.22 | -1.90 | -2.17 | -1.75 | -10.64 | -14.47 | -18.68 | -17.02 | -18.24 | -4.77 | -94.01 | -1.85 |
| EPS Diluted | -2.22 | -1.90 | -2.17 | -1.75 | -10.64 | -14.47 | -18.68 | -17.02 | -18.24 | -4.77 | -94.01 | -1.85 |
| Weighted Avg Shares Out | 36.37M | 20.07M | 15.79M | 11.59M | 7.17M | 5.87M | 5.13M | 4.83M | 3.15M | 3.88M | 140.59K | 3.88M |
| Weighted Avg Shares Out (Dil) | 36.37M | 20.07M | 15.79M | 11.59M | 7.17M | 5.87M | 5.13M | 4.83M | 3.15M | 3.88M | 140.59K | 3.88M |
Why Is Aravive (ARAV) Stock Down 52% Today?
Aravive stock slumps on Nasdaq delisting plan, dissolution
Aravive, Inc. to Delist from The Nasdaq Stock Market
Penny Stocks To Buy? Watch These 3 Under $5 Before Next Week
Aravive (ARAV) Upgraded to Strong Buy: What Does It Mean for the Stock?
Aravive (ARAV) Reports Q2 Loss, Tops Revenue Estimates
Why Is Aravive (ARAV) Stock Down 58% Today?
Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer
Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023
Aravive to Participate in William Blair's Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023
Source: https://incomestatements.info
Category: Stock Reports